The GU Cancer Channel on VJOncology is supported by Exelixis. The GU Cancer Channel is also supported by an educational grant from Pfizer Inc. and Merck KGaA. These supporters have no influence over the production of the content.
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
Phase II study of neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with MIBC
Jonathan Rosenberg • 5 Jun 2022
RECIP: a novel framework for treatment response evaluation using PSMA-PET/CT in patients with mCRPC
Andrei Gafita • 4 Jun 2022
How far away are we from implementing CTC-based approaches in prostate cancer?
Anis Hamid • 6 Jun 2022
Is there are role for 177Lu-PSMA-617 in earlier lines of treatment for mCRPC?
Scott Tagawa • 3 Jun 2022